Trastuzumab biosimilar - Celltrion

Drug Profile

Trastuzumab biosimilar - Celltrion

Alternative Names: CT-P06; CT-P6; Herzuma

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltrion
  • Developer Celltrion; Nippon Kayaku; Teva Pharmaceutical Industries
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer; Gastric cancer

Most Recent Events

  • 08 Sep 2017 Additional safety and efficacy from a phase III trial in Breast cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 31 Jul 2017 Preregistration for Breast cancer in USA (IV)
  • 31 Jul 2017 Preregistration for Gastric cancer (Metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top